Class action looms before Synovis
This article was originally published in Clinica
Executive Summary
Synovis Life Technologies is facing a barrage of class action charges, claiming the company had issued false and misleading financial statements between October 16 2003 and May 18 2004 in order to inflate its share price. The lawsuits - filed by several US law firms including Anatoly Weiser and Charles J. Piven - seek to represent investors who had purchased, converted, exchanged and acquired common stock in the St Paul, Minnesota company during that period.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.